Resultados de procura - M. E. Scheulen

  • Mostrando 1 - 14 Resultados de 14
Limitar resultados
  1. 1
    Ultradeep sequencing detects <scp><i>GNAQ</i></scp> and <scp><i>GNA11</i></scp> mutations in cell‐free <scp>DNA</scp> from plasma of patients with uveal melanoma

    Ultradeep sequencing detects <scp><i>GNAQ</i></scp> and <scp><i>GNA11</i></scp> mutations in cell‐free <scp>DNA</scp> from plasma of patients with uveal melanoma por Claudia H.D. Metz, M. E. Scheulen, Norbert Bornfeld, Dietmar Lohmann, Michael Zeschnigk

    Publicado 2013
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Cardiac troponin I plasma levels for diagnosis and quantitation of perioperative myocardial damage in patients undergoing coronary artery bypass surgery

    Cardiac troponin I plasma levels for diagnosis and quantitation of perioperative myocardial damage in patients undergoing coronary artery bypass surgery por V. Sadony, Michael Körber, Guido Albes, Volker Podtschaske, Thorleif Etgen, Thomas Trösken, Ursula Ravens, M. E. Scheulen

    Publicado 1998
    Ligazón do recurso Ligazón do recurso
    Carta
    Engadir a favoritos
    Gardado en:
  3. 3
    First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors

    First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors por K. Mross, Heike Richly, Richard Fischer, Dirk Scharr, Martin Büchert, Angelika C. Stern, Hendrik Gille, Laurent Audoly, M. E. Scheulen

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Risk factors for venous thromboembolic events in cancer patients

    Risk factors for venous thromboembolic events in cancer patients por Knut Kröger, Dorothea Weiland, Claudia Ose, Niklas Neumann, Steven J. Weiss, Calvin H. Hirsch, Krzysztof Urbański, S. Seeber, M. E. Scheulen

    Publicado 2005
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

    Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study por Dirk Strumberg, M. E. Scheulen, Beate Schultheis, Heike Richly, Annette Frost, Martin Büchert, O. Christensen, Michael Jeffers, Roland Heinig, Oliver Boix, K. Mross

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

    A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central... por K. Mross, Christian Dittrich, Walter E. Aulitzky, Dirk Strumberg, J. Schütte, Roland M. Schmid, S. Hollerbach, Michael Merger, Gerd Munzert, Frank Fleischer, M. E. Scheulen

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

    A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research... por Simone Steinbild, K. Mross, Annette Frost, R. Morant, Silke Gillessen, C. Dittrich, Dirk Strumberg, Andreas Hochhaus, A.-R. Hanauske, Lutz Edler, Iris Burkholder, M. E. Scheulen

    Publicado 2007
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

    Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors por Sebastian Bauer, R A Hilger, Thomas Mühlenberg, Florian Grabellus, James Nagarajah, Mathias Hoiczyk, Annette Reichardt, Marit Ahrens, Peter Reichardt, Susanne Grünewald, M. E. Scheulen, A. Pustowka, E Bock, Martin Schüler, Daniel Pink

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

    Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid... por Dirk Strumberg, Heike Richly, Ralf A. Hilger, N. Schleucher, Sönke Korfee, Mitra Tewes, Markus Faghih, E. Brendel, D. Voliotis, Claus G. Haase, Brian Schwartz, Ahmad Awada, R. Voigtmann, M. E. Scheulen, S. Seeber

    Publicado 2004
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

    Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors por Heike Richly, Bernhard F. Henning, P. Kupsch, K. Passarge, M. Grubert, Ralf A. Hilger, O. Christensen, E. Brendel, Brian Schwartz, Matthias Ludwig, C. Flashar, R. Voigtmann, M. E. Scheulen, S. Seeber, Dirk Strumberg

    Publicado 2006
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications

    Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased r... por Dietrich W. Beelen, Rudolf Trenschel, J. Casper, Mathias Freund, Ralf A. Hilger, M. E. Scheulen, Nadežda Basara, A. A. Fauser, Bernd Hertenstein, H. A. Mylius, Joachim Baumgart, Uwe Pichlmeier, J. Hahn, Ernst Holler

    Publicado 2004
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial

    Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial por Serge Leyvraz, Sophie Piperno‐Neumann, Stefan Suciu, J.F. Baurain, Marcin Zdzienicki, Alessandro Testori, Ernest Marshall, M. E. Scheulen, Thomas Jouary, Sylvie Négrier, Jan B. Vermorken, Eckhart Kaempgen, Xavier Durando, Dirk Schadendorf, Ravichandra Karra Gurunath, Ulrich Keilholz

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

    Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors por Suzanne Leijen, Mark R. Middleton, Patricia Tresca, Françoise Kraeber‐Bodéré, Véronique Dièras, M. E. Scheulen, Avinash Gupta, Vanesa López-Valverde, Zhixin Xu, Ruediger Rueger, Jean Tessier, Eliezer Shochat, Steve Blotner, Valérie Meresse Naegelen, Jan H.M. Schellens, Wilfried Eberhardt

    Publicado 2012
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer

    Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer por Stephen Chan, M. E. Scheulen, S. Johnston, K. Mross, Fátima Cardoso, Christian Dittrich, W. Eiermann, Dagmar Hess, Rudolph Morant, Semiglazov Vf, Markus Borner, Marc Salzberg, Valerijus Ostapenko, H. J. Illiger, Dirk Behringer, Nathalie Bardy‐Bouxin, Joseph Boni, Steven Kong, Maria Cincotta, Laurence Moore

    Publicado 2005
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: